Related Experiment Video
Updated: Jun 8, 2026
09:32
Network Analysis of Foramen Ovale Electrode Recordings in Drug-resistant Temporal Lobe Epilepsy Patients
Published on: December 18, 2016
[Cortexin in the complex treatment of post stroke epilepsy]
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova
|September 30, 2010
Summary
Adding Cortexin to standard treatment for post-stroke epilepsy significantly improved patient outcomes and EEG results. This therapy offers enhanced clinical effects for epilepsy patients following a stroke.
Area of Science:
- Neurology
- Clinical Pharmacology
Background:
- Post-stroke epilepsy is a common complication affecting patient recovery.
- Standard treatments may not always achieve optimal seizure control or neurological improvement.
Purpose of the Study:
- To evaluate the efficacy of Cortexin as an add-on therapy for post-stroke epilepsy.
- To assess the impact of Cortexin on clinical outcomes and electroencephalogram (EEG) findings.
Main Methods:
- A study involving 46 patients with post-stroke epilepsy.
- Comparison of a group receiving basic therapy plus Cortexin versus a group receiving only basic therapy (depakine-chrono and vascular drugs).
- Cortexin administered intramuscularly at 10 mg/day for 15 days.
Main Results:
- The group receiving add-on Cortexin showed significantly enhanced clinical effects.
- Positive changes were observed on electroencephalogram (EEG) in the Cortexin group.
- Basic therapy included depakine-chrono (750 mg/day) and vascular drugs.
Conclusions:
- Cortexin, as an add-on therapy, significantly improves clinical outcomes in patients with post-stroke epilepsy.
- The addition of Cortexin positively influences EEG parameters in this patient population.
- This suggests Cortexin is a valuable therapeutic option for managing post-stroke epilepsy.
More Related Videos
09:00Investigating the Function of Deep Cortical and Subcortical Structures Using Stereotactic Electroencephalography: Lessons from the Anterior Cingulate Cortex
Published on: April 15, 2015
09:07Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
Published on: August 15, 2017
Related Concept Videos
01:24Epilepsy and Seizures: Overview
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:13Seizures: Classification
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:19Seizures ll: Types
Seizures are sudden bursts of abnormal electrical discharge in the brain that interfere with normal function. They are commonly divided into three groups: focal seizures, generalized seizures, and other types that do not fit neatly into either category.Focal SeizuresFocal seizures begin in a single brain region. When awareness is preserved, they are called focal aware seizures and may cause sensations such as tingling, unusual smells, or flashing lights. When awareness is impaired, they are...
01:15Ischemic Stroke l: Introduction
Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.